

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|   |
|---|
| <b>Name of entity</b> Clarity Pharmaceuticals Ltd |
| <b>ABN</b> 36 143 005 341                         |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                  |
|----------------------------|------------------|
| <b>Name of Director</b>    | Alan John Taylor |
| <b>Date of last notice</b> | 26 August 2021   |

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>     | n/a  |
| <b>Date of change</b>   | 8 December 2022  |
| <b>No. of securities held prior to change:</b><br>Dr Alan Taylor<br><br>A.C.N 136 437 913 Pty Ltd ATF the Taylor Family Trust<br><br>Sally Taylor (spouse of Dr Taylor) | <ul style="list-style-type: none"> <li>• 600,000 options exercisable at \$0.605 each on or before 5 August 2024</li> <li>• 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024</li> <li>• 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025</li> <li>• 13,266,660 fully paid ordinary shares</li> <li>• 800,000 fully paid ordinary shares</li> </ul> |
| <b>Class</b>  | Options  |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |   |
|---|---|
| <b>Number acquired</b>  | 1,083,226 options exercisable at \$0.508 each on or before 24 November 2027   |
| <b>Number disposed</b>  | Nil   |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$871,003 using a Black-Scholes model with share price \$0.99 (5 day VWAP up to 23 November 2022).  |
| <b>No. of securities held after change</b><br>Dr Alan Taylor<br><br>A.C.N 136 437 913 Pty Ltd ATF the Taylor Family Trust<br><br>Sally Taylor (spouse of Dr Taylor)         | <ul style="list-style-type: none"> <li>• 600,000 options exercisable at \$0.605 each on or before 5 August 2024</li> <li>• 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024</li> <li>• 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025</li> <li>• 1,083,226 options exercisable at \$0.508 each on or before 24 November 2027</li> <li>• 13,266,660 fully paid ordinary shares</li> <li>• 800,000 fully paid ordinary shares</li> </ul> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of options following shareholder approval at AGM on 24 November 2022.   |

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | n/a |
| <b>Nature of interest</b>  | n/a |
| <b>Name of registered holder (if issued securities)</b>  | n/a |
| <b>Date of change</b>  | n/a |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed | n/a |
| <b>Interest acquired</b>   | n/a |

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

---

|   |     |
|---|-----|
| <b>Interest disposed</b>  | n/a |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | n/a |
| <b>Interest after change</b>  | n/a |

**Part 3 – <sup>+</sup>Closed period**

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | n/a |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | n/a |

---

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|   |
|---|
| <b>Name of entity</b> Clarity Pharmaceuticals Ltd |
| <b>ABN</b> 36 143 005 341                         |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                    |
|----------------------------|--------------------|
| <b>Name of Director</b>    | Colin David Biggin |
| <b>Date of last notice</b> | 1 July 2022        |

**Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | Direct   |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | n/a  |
| <b>Date of change</b>   | 8 December 2022  |
| <b>No. of securities held prior to change</b>   | <ul style="list-style-type: none"> <li>• 819,100 fully paid ordinary shares</li> <li>• 400,000 options exercisable at \$0.22 each on or before 14 February 2023</li> <li>• 1,000,000 options exercisable at \$0.22 each on or before 30 June 2023</li> <li>• 600,000 options exercisable at \$0.605 each on or before 1 July 2024</li> <li>• 1,000,000 options exercisable at \$0.605 each on or before 1 October 2024</li> <li>• 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024</li> <li>• 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025</li> </ul> |
| <b>Class</b>  | Options  |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|   |  |
|---|--|
| <b>Number acquired</b>  | 837,855 options exercisable at \$0.508 each on or before 24 November 2027  |
| <b>Number disposed</b>  | Nil  |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation   | \$673,704 using a Black-Scholes model with share price \$0.99 (5 day VWAP up to 23 November 2022).   |
| <b>No. of securities held after change</b>  | <ul style="list-style-type: none"> <li>• 819,100 fully paid ordinary shares</li> <li>• 400,000 options exercisable at \$0.22 each on or before 14 February 2023</li> <li>• 1,000,000 options exercisable at \$0.22 each on or before 30 June 2023</li> <li>• 600,000 options exercisable at \$0.605 each on or before 1 July 2024</li> <li>• 1,000,000 options exercisable at \$0.605 each on or before 1 October 2024</li> <li>• 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024</li> <li>• 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025.</li> <li>• 837,855 options exercisable at \$0.508 each on or before 24 November 2027</li> </ul> |
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Issue of options following shareholder approval at AGM on 24 November 2022   |

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |     |
|--|-----|
| <b>Detail of contract</b>  | n/a |
| <b>Nature of interest</b>  | n/a |
| <b>Name of registered holder (if issued securities)</b>  | n/a |
| <b>Date of change</b>  | n/a |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed | n/a |

+ See chapter 19 for defined terms.

Appendix 3Y  
Change of Director's Interest Notice

---

|  |     |
|--|-----|
| <b>Interest acquired</b>   | n/a |
| <b>Interest disposed</b>   | n/a |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation | n/a |
| <b>Interest after change</b>   | n/a |

**Part 3 – <sup>+</sup>Closed period**

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | No  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | n/a |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | n/a |

---

<sup>+</sup> See chapter 19 for defined terms.